Target intelligence / Profile preview

Cytochrome b561 family member D2 (CYB561D2)

Target
CYB561D2
Molecular classification
Transmembrane enzyme, Iron reductase, Cytochrome b561 family, Electron transfer protein
01

Overview

Cytochrome b561 family member D2 (CYB561D2) is a transmembrane heme-containing protein that functions primarily as a monodehydroascorbate reductase and iron reductase, enabling electron transfer from ascorbate in the cytoplasm to ferric ions and monodehydroascorbate in the endoplasmic reticulum lumen. It regulates cellular ascorbate and iron homeostasis and is implicated in redox balance and immune modulation via STAT3 pathway activation in tumors, particularly gliomas. CYB561D2 acts as a putative tumor suppressor when deleted or downregulated (notably in lung cancer), but its upregulation in glioma promotes tumor aggression and immunosuppression through induction of PD-L1 and related genes. Located on human chromosome 3p21.3, a region frequently deleted in cancer, its expression level serves as a biomarker for prognosis and may present a future pathway for therapeutic intervention, although targeted drugs are still investigational.

Other names
101F6LUCA12.2TSP10TSCytbCytochrome b561 domain-containing protein 2Putative tumor suppressor protein 101F6transmembrane ascorbate ferrireductasetumor suppressor cytochrome b561XXcos-LUCA11.4
02

Mechanism of action

Electron transport from cytoplasmic ascorbate across endoplasmic reticulum membrane to reduce lumenal monodehydroascorbate and ferric ions (Fe³⁺); modulation of STAT3 signaling and downstream immune regulatory genes such as PD-L1, CCL2, TDO2 in tumor cells

03

Biological functions

Iron metabolismAscorbate homeostasisElectron transportReactive oxygen species (ROS) regulationImmunomodulationTumor suppression or promotion (context-dependent)Apoptosis inductionCell cycle controlCell migration
04

Disease associations

Cancer (lung cancer, glioma, renal cell carcinoma, other solid tumors)Neurodegenerative disease (via iron metabolism dysregulation)Cerebellar atrophy with seizures and developmental delay
05

Safety considerations

Unknown or unspecified in clinical context for direct targetingpotential concerns in modulating iron homeostasis, ROS balance, or immune pathways
06

Interacting drugs

ascorbate (vitamin C)

1 more in the full profile.

07

Biomarkers

Positive/negative prognostic factor in lung cancer and glioma (CYB561D2 expression)potentially predictive of tumor immune response or efficacy of immunotherapy (PD-L1 association)

Beyond the preview

Go deeper on Cytochrome b561 family member D2 (CYB561D2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cytochrome b561 family member D2 (CYB561D2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call